Recursion Pharmaceuticals Shares Rise on Positive Drug Data and Cash Runway Extension
Recursion Pharmaceuticals (RXRX) reported encouraging Phase 1b/2 trial results for its experimental drug REC-4881 alongside several corporate updates. Shares of the biotech firm climbed over 11% following the announcement. In the study, REC-4881 achieved an 87% mean drop and a 47% median reduction in gastrointestinal polyp burden at Week 12, with durable responses maintained through Week 25. Upper gastrointestinal polyp burden fell by 92%, while safety data was favorable with no treatment-related adverse events exceeding Grade 3.
The positive trial outcomes arrive alongside key funding developments that solidify the company's financial timeline. Sanofi exercised an option on the first candidate in its ongoing collaboration, generating an immediate $10 million milestone payment for Recursion Pharmaceuticals. With approximately $561 million in cash as of September 30, 2026, plus an expected $200 million in gross proceeds from an October 2026 offering, the business expects its cash runway to last into 2029.
Looking ahead, Recursion Pharmaceuticals plans to start a registrational trial for REC-4881 in the second half of 2027 following discussions with regulatory bodies. The company is also seeking strategic partners for two candidates, REC-617 and REC-3565, while continuing clinical progress across several other pipeline programs.
Key points
- REC-4881 achieved an 87% mean reduction in gastrointestinal polyp burden at Week 12 with clean safety results.
- Sanofi exercised a collaboration option, triggering an immediate $10 million cash milestone payment to Recursion Pharmaceuticals.
- The company held $561 million in cash as of late September 2026 and expects $200 million from a capital offering.
- Recursion Pharmaceuticals projects its current cash reserves will fund operations into 2029.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were the results of Recursion Pharmaceuticals' REC-4881 trial?
In a Phase 1b/2 study, REC-4881 demonstrated an 87% mean reduction in gastrointestinal polyp burden at Week 12. Response durability was maintained at Week 25, and no treatment-related adverse events above Grade 3 were observed.
How long is Recursion Pharmaceuticals' cash runway?
Recursion Pharmaceuticals expects its cash runway to extend into 2029, supported by $561 million in cash as of September 30, 2026, alongside $200 million in expected gross proceeds from an October 2026 offering.
When will the next clinical trial for REC-4881 begin?
Recursion Pharmaceuticals plans to launch a registrational trial for REC-4881 in the second half of 2027, pending discussions with regulatory authorities.